Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Abrocitinib Looks Competitive In Atopic Dermatitis

Executive Summary

The first detailed Phase III results for the company's next-generation oral JAK inhibitor abrocitinib appear to show efficacy on par or better than data from Sanofi/Regeneron's Dupixent and may give Lilly's Olumiant a run for its money in AD.

You may also be interested in...



A Slimmed-Down Pfizer Sets A New R&D Goal: 25 Launches By 2025

The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.

AbbVie’s Rinvoq Shines In First Of Three Eczema Pivotal Studies

The JAK1 inhibitor showed skin clearance and itch reduction in first of three Phase III trials. Analysts say blockbuster atopic dermatitis indication is possible if data hold up in ongoing studies.

Deal Watch: Pfizer Licenses Skin-Targeted JAK Inhibitor Portfolio From Theravance

Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel